Biogen has confirmed plans to purchase a 49.9% equity stake in the Samsung Bioepis biosimilars joint venture between itself and Samsung BioLogics, praising the “attractive, value-creation opportunity”.
Biogen has confirmed plans to purchase a 49.9% equity stake in the Samsung Bioepis biosimilars joint venture between itself and Samsung BioLogics, praising the “attractive, value-creation opportunity”.
“In the coming months, we plan to exercise our option,” executive vice-president and chief financial officer Jeffrey Capello told investors, as Biogen reported biosimilar sales for the first
Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.
During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.
Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.
Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.
